of the novel anti-asthma agent IRL576,092 (2) is described. The synthetic route developed involves stereoselective 1,2-reduction of the enone carbonyl functionality of 6 and subsequent hydroboration as the key steps. Starting from the commercially available 5-androsten-3beta-ol-17-one 3, this approach affords IPL576,092 (2) in nine steps with overall yields of 25%, employing a limited number of chromatographic
描述了新型抗哮喘药IRL576,092(2)的对映体合成。所开发的合成途径涉及关键步骤,即立体选择性地还原6的烯酮羰基官能团,然后进行
硼氢化。从市售的5-androsten-3beta-ol-17-one 3开始,采用有限数量的色谱步骤,该方法分9个步骤提供IPL576,092(2),总产率为25%。